Chitogel has developed a bioresorbable hydrogel technology that improves surgical outcomes and patient wellbeing after functional endoscopic sinus surgeries. Developing a compound which has several clinically proven benefits from a derivative of chitosan, Chitogel demonstrates anti-inflammatory properties and the ability to modulate wound healing within the nasal passage, helping to prevent a range of adverse events and complications in post surgery sites. 

Developed at the University of Otago, the company has a strong patent portfolio and regulatory profile. Already in clinical use and distributed by Medtronics, Chitogel has seen adoption by clinical practitioners both nationally and in the USA.